Abstract
Brain glucose hypometabolism has been observed in Alzheimer’s disease (AD) patients, and is detected with 18F radiolabelled glucose, using positron emission tomography. A pathological hallmark of AD is deposition of brain β- amyloid plaques that may influence cerebral glucose metabolism. The five times familial AD (5XFAD) mouse is a model of brain amyloidosis exhibiting AD-like phenotypes. This study examines brain β-amyloid plaque deposition and 18FDG uptake, to search for an early biomarker distinguishing 5XFAD from wild-type mice. Thus, brain 18FDG uptake and plaque deposition was studied in these mice at age 2, 5 and 13 months. The 5XFAD mice demonstrated significantly reduced brain 18FDG uptake at 13 months relative to wild-type controls but not in younger mice, despite substantial β- amyloid plaque deposition. However, by comparing the ratio of uptake values for glucose in different regions in the same brain, 5XFAD mice could be distinguished from controls at age 2 months. This method of measuring altered glucose metabolism may represent an early biomarker for the progression of amyloid deposition in the brain. We conclude that brain 18FDG uptake can be a sensitive biomarker for early detection of abnormal metabolism in the 5XFAD mouse when alternative relative uptake values are utilized.
Keywords: Alzheimer's disease, β-amyloid, computed tomography, glucose metabolism, magnetic resonance imaging, positron emission tomography, standardized uptake value, Tg6799.
Current Alzheimer Research
Title:Early Detection of Cerebral Glucose Uptake Changes in the 5XFAD Mouse
Volume: 11 Issue: 5
Author(s): I.R. Macdonald, D.R. DeBay, G.A. Reid, T.P. O’Leary, C.T. Jollymore, G. Mawko, S. Burrell, E. Martin, C.V. Bowen, R.E. Brown and S. Darvesh
Affiliation:
Keywords: Alzheimer's disease, β-amyloid, computed tomography, glucose metabolism, magnetic resonance imaging, positron emission tomography, standardized uptake value, Tg6799.
Abstract: Brain glucose hypometabolism has been observed in Alzheimer’s disease (AD) patients, and is detected with 18F radiolabelled glucose, using positron emission tomography. A pathological hallmark of AD is deposition of brain β- amyloid plaques that may influence cerebral glucose metabolism. The five times familial AD (5XFAD) mouse is a model of brain amyloidosis exhibiting AD-like phenotypes. This study examines brain β-amyloid plaque deposition and 18FDG uptake, to search for an early biomarker distinguishing 5XFAD from wild-type mice. Thus, brain 18FDG uptake and plaque deposition was studied in these mice at age 2, 5 and 13 months. The 5XFAD mice demonstrated significantly reduced brain 18FDG uptake at 13 months relative to wild-type controls but not in younger mice, despite substantial β- amyloid plaque deposition. However, by comparing the ratio of uptake values for glucose in different regions in the same brain, 5XFAD mice could be distinguished from controls at age 2 months. This method of measuring altered glucose metabolism may represent an early biomarker for the progression of amyloid deposition in the brain. We conclude that brain 18FDG uptake can be a sensitive biomarker for early detection of abnormal metabolism in the 5XFAD mouse when alternative relative uptake values are utilized.
Export Options
About this article
Cite this article as:
Macdonald I.R., DeBay D.R., Reid G.A., O’Leary T.P., Jollymore C.T., Mawko G., Burrell S., Martin E., Bowen C.V., Brown R.E. and Darvesh S., Early Detection of Cerebral Glucose Uptake Changes in the 5XFAD Mouse, Current Alzheimer Research 2014; 11 (5) . https://dx.doi.org/10.2174/1567205011666140505111354
DOI https://dx.doi.org/10.2174/1567205011666140505111354 |
Print ISSN 1567-2050 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5828 |
Call for Papers in Thematic Issues
New Advances in the Prevention, Diagnosis, Treatment, and Rehabilitation of Alzheimer's Disease
Aims and Scope: Introduction: Alzheimer's disease (AD) poses a significant global health challenge, with an increasing prevalence that demands concerted efforts to advance our understanding and strategies for prevention, diagnosis, treatment, and rehabilitation. This thematic issue aims to bring together cutting-edge research and innovative approaches from multidisciplinary perspectives to address ...read more
Current updates on the Role of Neuroinflammation in Neurodegenerative Disorders
Neuroinflammation is an invariable hallmark of chronic and acute neurodegenerative disorders and has long been considered a potential drug target for Alzheimer?s disease (AD) and dementia. Significant evidence of inflammatory processes as a feature of AD is provided by the presence of inflammatory markers in plasma, CSF and postmortem brain ...read more
Deep Learning for Advancing Alzheimer's Disease Research
Alzheimer's disease (AD) poses a significant global health challenge, with an increasing number of individuals affected yearly. Deep learning, a subfield of artificial intelligence, has shown immense potential in various domains, including healthcare. This thematic issue of Current Alzheimer Research explores the application of deep learning techniques in advancing our ...read more
Diagnostic and therapeutic biomarkers of dementia
Dementia affects 18 million people worldwide. Dementia is a syndrome of symptoms caused by brain disease, usually chronic or progressive, clinically characterized by multiple impairments of higher cortical functions such as memory, thinking, orientation, and learning. In addition, in the course of dementia, cognitive deficits are observed, which often hinder ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Editorial [Hot topic:Food Addiction & Obesity Treatment Development (Executive Guest Editors: Mark S. Gold and Noni A. Graham)]
Current Pharmaceutical Design Applications of HPLC-MALDI-TOF MS/MS Phosphoproteomic Analysis in Oncological Clinical Diagnostics
Current Proteomics TRPV1 and Synaptic Transmission
Current Pharmaceutical Biotechnology Bridging Neurocognitive Aging and Disease Modification: Targeting Functional Mechanisms of Memory Impairment
Current Alzheimer Research The Role of Executive Functioning in PTSD and its Treatment
Current Psychiatry Reviews Multi-Target-Directed Ligands in Alzheimer's Disease Treatment
Current Medicinal Chemistry Endogenous Retroviruses in Domestic Animals
Current Genomics Is the Modulation of Autophagy the Future in the Treatment of Neurodegenerative Diseases?
Current Topics in Medicinal Chemistry Supplementation with Curcuma longa Reverses Neurotoxic and Behavioral Damage in Models of Alzheimer’s Disease: A Systematic Review
Current Neuropharmacology The Promise of Plant Polyphenols as the Golden Standard Skin Anti-Inflammatory Agents
Current Drug Metabolism Crystallization and Preliminary X-ray Diffraction Analysis of CsaA from P. torridus: A Chaperone Rarely Found in Archaea
Current Chemical Biology Effects of Palmitoylethanolamide and Luteolin in an Animal Model of Anxiety/Depression
CNS & Neurological Disorders - Drug Targets Strategies that Target Tight Junctions for Enhanced Drug Delivery
Current Pharmaceutical Design Late-life Depression and Alzheimer Disease: A Potential Synergy of the Underlying Mechanisms
Current Medicinal Chemistry How Cardiomyocytes Make the Heart Old
Current Pharmaceutical Biotechnology The In Silico Prediction of Human-Specific Metabolites from Hepatotoxic Drugs
Current Drug Discovery Technologies Successful Applications of Computer Aided Drug Discovery: Moving Drugs from Concept to the Clinic
Current Topics in Medicinal Chemistry Commentary 1 (Research Highlights: Parkinson’s Disease and α-Synuclein: Passing it on)
CNS & Neurological Disorders - Drug Targets Synthesis, Characterization and Screening for Analgesic and Anti-inflammatory activities of 2, 5-disubstituted 1, 3, 4-oxadiazole derivatives
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Energy Metabolism Impairment in Migraine
Current Medicinal Chemistry